Research programme: metabotropic glutamate receptor modulators - AstraZeneca
Alternative Names: CPPZ; NPS 2398; NPS-2390Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator AstraZeneca; NPS Pharmaceuticals
- Developer AstraZeneca; National Institute of Drug Abuse
- Class Quinoxalines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 modulators; Metabotropic glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; CNS disorders; Epilepsy; Pain; Schizophrenia; Stroke; Substance-related disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in USA